According to a recent LinkedIn post from Strive Health, the company is drawing attention to the underutilization of SGLT2 inhibitors for kidney disease and cardiovascular risk reduction, despite strong clinical evidence. The post notes that only about 20% of eligible patients currently access these therapies, with administrative and affordability barriers cited as key obstacles.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights a new white paper by Chief Nephrologist Keith A. Bellovich, D.O., which outlines three main barriers payors face in enabling broader SGLT2 use and discusses how integrated care models may help address them. For investors, this focus suggests Strive Health is positioning itself as a solution provider in value-based kidney care, potentially enhancing its relevance to payors seeking lower total cost of care and improved clinical outcomes.
The emphasis on implementation challenges, such as prior authorization delays and care transition gaps, indicates that Strive’s offerings may target operational frictions rather than drug development itself. If the company can demonstrate measurable improvements in SGLT2 therapy uptake and associated cost savings, it could strengthen its competitive position in the kidney health management and value-based care segments.
As health plans continue to manage rising costs in chronic kidney disease and cardiovascular care, the themes in this post suggest an addressable market for services that streamline therapy access and adherence. This positioning could support future commercial traction or partnership opportunities with payors and providers that are seeking scalable, evidence-aligned care models.